http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-200401059-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04 |
| filingDate | 2003-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-200401059-A1 |
| titleOfInvention | ATORVASTATIN COMPOSITIONS STABILIZED BY ALKALINE METAL ADDITIVES |
| abstract | A pharmaceutical composition having improved bioavailability and bioequivalence includes amorphous and / or crystalline atorvastatin particles, the size of which (d) is less than 150 microns and the average size of which (d) is approximately 5 to 50 microns. Atorvastatin can be one or more salts from the range of atorvastatin-calcium, atorvastatin-magnesium, atorvastatin-aluminum, atorvastatin-iron and atorvastatin-zinc. Atorvastatin compositions can be stabilized by mixing with the addition of an alkali metal salt at a concentration of from about 1.2% to less than 5% by weight of the composition. The addition of an alkali metal salt can be one or more of sodium carbonate, sodium bicarbonate, sodium hydroxide, sodium silicate, sodium hydrogen phosphate, sodium dihydrogen phosphate, sodium hydrogen phosphate, sodium phosphate, sodium aluminate, calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide salts , magnesium silicate, magnesium aluminate and aluminum hydroxide magnesium. Atorvastatin compositions can be used to treat medical conditions that include primary hypercholesterolemia, dysbetalipoproteinemia and homozygous familial hypercholesterolemia. The international application was published with an international search report. |
| priorityDate | 2002-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.